ReviewiScience2026
Decoding chemerin proteolytic processing and isoform signaling across disease contexts.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemerin (RARRES2) is a multifunctional adipokine widely implicated in metabolic, inflammatory, cardiovascular, and neoplastic diseases, yet its clinical interpretation remains confounded by reliance on "total chemerin" measurements that obscure its proteoform-specific signaling. This single value is mechanistically misleading because chemerin is secreted as an inactive precursor and undergoes extracellular proteolytic processing into C-terminal isoforms with graded receptor potency and compartment-specific distribution. This review decodes chemerin's functional duality through three integrated layers: (1) protease-encoded isoform "barcodes" that dictate bioactivity, (2) compartment-specific isoform landscapes in human biofluids and disease microenvironments, and (3) receptor context across CMKLR1, GPR1, and CCRL2 that shapes signaling output. We provide a conceptual roadmap for translating chemerin biology, emphasizing isoform-resolved quantification via targeted /MRM-MS and a compartment-aware framework for interpreting clinical associations. This framework helps interpret heterogeneous disease associations and highlights testable entry points for context-specific targeting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.